GlassScriptPhysician profile
Thomas D Mcdonald
NPI 1710956289
$12,229.10
in general payments reported to CMS, 2019-2025
66 companies · $3,096 in 2025
The $3,096 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $260 · 2021: $429 · 2022: $2,420 · 2023: $3,346 · 2024: $2,569 · 2025: $3,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,605 · Education: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,605.11 |
| Education | $405.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,525.94 | 2021-2025 | |
| Pfizer INC. | $907.86 | 2023-2025 | |
| Emd Serono, INC. | $731.56 | 2019-2025 | Mavenclad |
| Jazz Pharmaceuticals INC. | $581.32 | 2021-2025 | Xywav, Epidiolex |
| Alexion Pharmaceuticals, INC. | $547.64 | 2019-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $495.42 | 2020-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $438.85 | 2019-2025 | Skyclarys, Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $433.40 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $406.96 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Ucb, INC. | $402.56 | 2022-2025 | Nayzilam, Fintepla, Briviact |
| Sk Life Science, INC. | $381.07 | 2021-2025 | Xcopri |
| Harmony Biosciences LLC | $372.19 | 2022-2024 | Wakix |
| Eisai INC. | $368.39 | 2022-2025 | |
| Genzyme Corporation | $310.65 | 2021-2025 | |
| Tg Therapeutics, INC. | $278.53 | 2023-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $253.16 | 2022-2025 | Uplizna, Aimovig |
| Lilly USA, LLC | $237.64 | 2020-2025 | Reyvow, Emgality, Amyvid |
| Argenx US, INC. | $225.08 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Tanabe Pharma America, INC. | $221.57 | 2019-2025 | Radicava |
| Ipsen Biopharmaceuticals, INC | $176.09 | 2022-2025 | Dysport |
| Vanda Pharmaceuticals INC. | $171.23 | 2024-2025 | Ponvory |
| Genentech USA, INC. | $164.39 | 2020-2024 | Ocrevus, Ocrevus Zunovo |
| Biohaven Pharmaceutical Holding Company LTD. | $154.65 | 2022 | |
| Acadia Pharmaceuticals INC | $141.38 | 2023-2025 | Nuplazid, Daybue |
| Neurelis, INC. | $128.59 | 2022-2024 | Valtoco |
| Ani Pharmaceuticals, INC. | $126.29 | 2022-2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $124.70 | 2020-2025 | Infinity |
| Octapharma USA, INC. | $115.25 | 2022-2023 | Panzyga |
| Acorda Therapeutics, INC | $112.82 | 2022-2023 | Inbrija |
| Amneal Pharmaceuticals LLC | $107.34 | 2022-2023 | Rytary |
| Mdd US Operations, LLC | $95.14 | 2022-2024 | Apokyn |
| Celgene Corporation | $92.51 | 2022-2024 | Zeposia |
| Catalyst Pharmaceuticals, INC. | $91.13 | 2023-2025 | Firdapse |
| Avion Pharmaceuticals | $89.15 | 2022-2023 | Dhivy |
| Alnylam Pharmaceuticals INC. | $84.50 | 2022-2024 | Amvuttra |
| Otsuka America Pharmaceutical, INC. | $84.49 | 2023-2024 | Rexulti, Nuedexta |
| Mallinckrodt Hospital Products INC. | $70.62 | 2023-2025 | Acthar |
| Lundbeck LLC | $66.49 | 2023-2024 | Rexulti, Vyepti |
| Collegium Pharmaceutical, INC. | $66.21 | 2022 | |
| Insightec,INC | $63.07 | 2023 | Exablate |
| Allergan, INC. | $61.63 | 2019-2021 | |
| Banner Life Sciences, LLC | $56.63 | 2022-2023 | |
| Neuropace, INC. | $49.73 | 2023-2025 | |
| Livanova USA, INC. | $48.28 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Avadel Cns Pharmaceuticals, LLC | $48.21 | 2023-2025 | Lumryz |
| Ultragenyx Pharmaceutical INC. | $41.79 | 2022 | |
| Philips North America LLC | $41.51 | 2023 | |
| Kyowa Kirin, INC. | $40.02 | 2020-2023 | Nourianz |
| Horizon Therapeutics Plc | $37.54 | 2021-2023 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $36.92 | 2020 | |
| Grt US Holding, INC. | $34.86 | 2022 | |
| Merz North America, INC. | $31.03 | 2020 | |
| Nevro Corp. | $28.07 | 2022 | |
| Grifols USA, LLC | $25.29 | 2022 | |
| Ge Healthcare | $24.75 | 2025 | |
| Avanir Pharmaceuticals, INC. | $22.73 | 2022 | |
| Averitas Pharma INC. | $21.55 | 2024 | Qutenza |
| Genentech, INC. | $21.21 | 2024 | Ocrevus |
| Vertical Pharmaceuticals, LLC | $21.05 | 2020 | |
| Csl Behring | $19.59 | 2025 | Hizentra |
| Life Molecular Imaging LTD | $19.16 | 2025 | Neuraceq |
| Astrazeneca Pharmaceuticals LP | $18.26 | 2022 | |
| Boston Scientific Corporation | $17.88 | 2022 | |
| Axsome Therapeutics, INC. | $15.58 | 2025 | Symbravo |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.